TNFRSF9 and neoplasm: To evaluate the potential of co-stimulatory receptor targeting in anti-tumor immunotherapy, TNFSRF member (GITR, 4-1BB, and/or OX40) expression was measured ex vivo on CD4+ T cells from pMMR CRC and CRLM patients.